Adjuvant Endocrine Therapy for Breast Cancer During Perimenopause

被引：1
|
作者：
Noss, D. [1 ]
Buchholz, S. [1 ]
Ortmann, O. [1 ]
机构：
[1] Univ Regensburg, Klin Frauenheilkunde & Geburtshilfe, D-93053 Regensburg, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2010年 / 70卷 / 02期
关键词：
perimenopause; breast cancer; endocrine therapy; menopausal status; PREMENOPAUSAL WOMEN; AROMATASE INHIBITORS; HORMONE; CHEMOTHERAPY; METAANALYSIS; TAMOXIFEN;
D O I：
10.1055/s-0029-1240825
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Adjuvant endocrine treatment plays an important role in the treatment of estrogen responsive breast cancer. The treatment options for premenopausal women differ from those for postmenopausal women. Aromatase inhibitors (AI) improve the outcomes in postmenopausal women, while AI can induce an increase in estrogen secretion and tumor growth in premenopausal women. The standard therapy during premenopause remains tamoxifen with or without ovarian suppression by GnRH analogues. Treatment of perimenopausal breast cancer patients can be more complicated, because it is often difficult to determine menopausal status.
引用
收藏
页码：112 / 116
页数：5
相关论文
共 50 条
  • [21] Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer
    Bracken-Clarke, Dara B.
    Lucas, Mairi W.
    Higgins, Michaela J.
    BREAST CARE, 2017, 12 (03) : 138 - 144
  • [22] Adjuvant endocrine therapy and risk of contralateral breast cancer: a systematic review and meta-analysis of observational studies
    Ghosh, Rajrupa
    Pfeiffer, Ruth M.
    Roberts, Sylvia
    Gierach, Gretchen L.
    Dallal, Cher M.
    CANCER CAUSES & CONTROL, 2025, 36 (02) : 107 - 126
  • [23] New developments in endocrine therapy - Role of adjuvant therapy for early breast cancer
    Grana, G
    CANCER NURSING, 2003, 26 (06) : 4S - 9S
  • [24] Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer
    Katherine E. Reeder-Hayes
    Anne Marie Meyer
    Stacie B. Dusetzina
    Huan Liu
    Stephanie B. Wheeler
    Breast Cancer Research and Treatment, 2014, 145 : 743 - 751
  • [25] Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer
    Robinson, B.
    Dijkstra, B.
    Davey, V.
    Tomlinson, S.
    Frampton, C.
    CLINICAL ONCOLOGY, 2018, 30 (01) : E9 - E15
  • [26] Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer
    Mundhenke, Christoph
    Schem, Christian
    Jonat, Walter
    BREAST CARE, 2008, 3 (05) : 317 - 324
  • [27] Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women
    Rossi, Lorenzo
    Pagani, Olivia
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (05)
  • [28] PREVENTION OF BREAST-CANCER RECURRENCE WITH ADJUVANT CYTOTOXIC OR ENDOCRINE THERAPY
    RUTQVIST, LE
    MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1991, 8 (03): : 163 - 168
  • [29] Optimal adjuvant endocrine therapy for early breast cancer
    Stuart-Harris, Robin
    Davis, Alison
    WOMENS HEALTH, 2010, 6 (03) : 383 - 398
  • [30] Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
    Ward, John H.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (01) : 51 - 55
12345